Anuh Pharma (506260) Q1 26/27 earnings summary

Executive summary

• Board approved unaudited financial results for the quarter ended 30th June 2026, with review by statutory auditors and audit committee.

• Promoter group members withdrew requests for reclassification to public category and will remain promoters.

• Revised policy on related party transactions adopted and published on the company website.

Financial highlights

• Revenue from operations for Q1 FY27 was ₹19,381.04 lakhs, up from ₹18,647.94 lakhs year-over-year but down from ₹20,211.72 lakhs sequentially.

• Net profit after tax for the quarter was ₹1,142.49 lakhs, compared to ₹830.12 lakhs in Q1 FY26 and ₹1,168.14 lakhs in Q4 FY26.

• EBITDA for the quarter was ₹1,936.44 lakhs, with an EBITDA margin of 9.99% (up from 7.34% year-over-year).

• Basic and diluted EPS for the quarter stood at ₹1.14, compared to ₹0.83 in Q1 FY26.

Outlook and guidance

• No explicit forward-looking guidance provided, but continued focus on core bulk drug and chemicals segment.